Outcome following tranexamic acid exposure during breastfeeding

Breastfeeding Medicine

Volumn 9, Issue 8, 2014, Pages 407-410

  Gilad, Oded ^a,b   Merlob, Paul ^a,b,c   Stahl, Bracha ^c   Klinger, Gil ^a,b,c  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; ARTICLE; BREAST FEEDING; BREAST MILK; CHILD DEVELOPMENT; CHILD GROWTH; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; INFANT; LACTATION; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; RESTLESSNESS; THROMBOCYTOPENIA; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FAILURE TO THRIVE; MOTHER; NEWBORN; POSTPARTUM HEMORRHAGE; PREGNANCY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANTIFIBRINOLYTIC AGENTS; BREAST FEEDING; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FAILURE TO THRIVE; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; INFANT; INFANT, NEWBORN; LACTATION; MILK, HUMAN; MOTHERS; POSTPARTUM HEMORRHAGE; PREGNANCY; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRANEXAMIC ACID;

EID: 84912130276     PISSN: 15568253     EISSN: 15568342     Source Type: Journal    
DOI: 10.1089/bfm.2014.0027     Document Type: Article

References (23)

1. McCormack PL. Tranexamic acid, a review of its use in the treatment of hyperfibrinolysis. Drugs 2012;72:585-617.
2. Lysteda Oral Tablets, Tranexamic Acid Oral Tablets [product information]. Xanodyne Pharmaceuticals, Inc., Newport, KY, 2009.
3. Cyklokapron Intravenous Injection, Tranexamic Acid Intravenous Injection [product information]. Pharmacia & Upjohn Co., New York, 2013.
4. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstet Gynecol 2010;116:865-875.
5. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: A randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996;313:579-582.
6. Preston JT, Cameron IT. Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995;102:401-406.
7. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164:879-883.
8. Kouides PA. Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: A prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009;145:212-220.
9. Ducloy-Bouthors AS, Jude B, Duhamel A, et al. High dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011;15:R117.
10. Gungorduk K, Yildirim G, Asicioglu O, et al. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: A prospective, randomized doubleblind, placebo-controlled study. Am J Perinatol 2011;28: 233-239.
11. Sekhavat L, Tabatabaii A, Dalili M, et al. Efficacy of tranexamic acid in reducing blood loss after cesarean section. J Matern Fetal Neonatal Med 2009;22:72-75.
12. Gai MY, Wu LF, Su QF, et al. Clinical observation of blood loss reduced by tranexamic acid during and after Caesarian section: A multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol 2004;112:154-157.
13. Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynaecol Obstet 2011; 115:224-226.
14. Shakur H, Elbourne D, Gülmezoglu M, et al. The woman Trial (World Maternal Antifibrinolytic Trial): Tranexamic acid for the treatment of postpartum haemorrhage: An international randomised, double blind placebo controlled trial. Trials 2010;11:40.
15. Phupong V, Sophonsritsuk A, Taneepanichskul S. The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplantuse. Contraception 2006; 73:253-256.
16. Tranexamic acid. In: Medications and Mother's Milk, 15th ed. Hale Publishing, Amarillo, TX, 2012, pp. 1096-1097.
17. Cyklokapron (Pharmacia). In: Krogh CME, ed. Compendium of Pharmaceutical and Specialties, 28th ed. Canadian Pharmaceutical Association, Ottawa, 1993, pp. 311-312.
18. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129:308-320.
19. Schaefer C, Ornoy A, Clementi M, et al. Using observational cohort data for studying drug effects on pregnancy outcome-Methodological considerations. Reprod Toxicol 2008;26:36-41.
20. Goldstein LH, Berlin M, Tsur L, et al. The safety of macrolides during lactation. Breastfeed Med 2009;4:197-200.
21. Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding. Cochrane Database Syst Rev 2012;8: CD003517.
22. The Optimal Duration of Exclusive Breastfeeding. Report of an Expert Consultation. Document WHO/NHD/01.09, WHO/FCH/CAH/01.24. Department of Nutrition for Health and Development, Department of Child Care and Adolescent Health and Development, World Health Organization, Geneva, 2001.
23. Gartner LM, Morton J, Lawrence RA, et al. Breastfeeding and the use of human milk. Pediatrics 2005;115:496-506.